Abstract
With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article. For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. This Focus Issue on arrhythmias contains the ‘2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC), endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC)’.1 The first general part has new sections on diagnostic evaluation, including pharmacological provocative tests, genetic testing, and a systematic work-up of probands and relatives with primary electrical diseases. Comprehensive flowcharts and recommendations for the diagnostic evaluation at first presentation with a ventricular arrythmia (VA) of patients without a previously known cardiac disease are provided for five frequently encountered clinical scenarios. Practical recommendations for optimization of implantable cardioverter defibrillator programming and algorithms for management of patients experiencing regular wide complex tachycardia and electrical storm are presented. The second part of the guidelines is structured according to disease-specific management, providing a link to the updated ESC CardioMed chapter for additional content. Risk stratification, sudden cardiac death prevention, treatment of VA, and management of family members are addressed in a systematic fashion. Indications for cardiac magnetic resonance imaging, genetic testing, and updated indications for catheter ablation of ventricular arrhythmias are presented. Flowcharts summarizing the workflow for diagnostis and treatment are provided for the disease entities. A novel concept of this document is the table of evidence. The trials and studies that have been selected to support a recommendation are systematically described in the table of evidence after careful review of the available data and the applied methodology, prioritizing papers published after 2015. Strong mediating and moderating effect of sinus rhythm at 12 months on the first primary outcome of the EAST-AFNET 4 trial. The presence of sinus rhythm at 12 months explains about 81% of the effect of early rhythm control on the first primary outcome, a composite of cardiovascular death, stroke, or hospitalization for heart failure, or acute coronary syndrome. This can be appreciated in the first horizontal line in the graph (natural effect). There is hardly any effect of early rhythm control in patients who are not in sinus rhythm at the 12-month visit, visible in lack of a controlled direct effect in patients not in sinus rhythm at 12 months. Atrial fibrillation recurrence at any time up to the 12-month visit, in contrast, only explains 31% of the effect of early rhythm control, due to the small differences between the effects of the two subgroups (controlled effect in patients without AF recurrence and patients with AF recurrence). The analysis is adjusted for baseline characteristics that may confound the treatment effects on the mediator or the mediator effect on the outcome. Total effect indicates the adjusted treatment effect on the outcome; natural direct effect indicates the adjusted treatment effect due to the observed distribution of the mediator; controlled direct effect indicates the adjusted treatment effect for subgroups of patients with and without sinus rhythm or with and without atrial fibrillation recurrence at 12 months.5 Several factors can affect sinus rhythm, and recent studies have suggested that its preservation may have a beneficial effect on prognosis.2–4 In a Fast Track Clinical Research article entitled ‘Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial’, Lars Eckardt, from the University Hospital Münster in Germany, and colleagues point out that a strategy of systematic, early rhythm control (ERC) improves cardiovascular outcomes in patients with atrial fibrillation (AF). It is not known how this outcome-reducing effect is mediated.5 Using the Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST—AFNET 4) dataset, potential mediators of the effect of ERC were identified in the total study population at 12-month follow-up and were further interrogated by use of a four-way decomposition of the treatment effect in an exponential model predicting future primary outcome events. Fourteen potential mediators of ERC were identified at the 12-month visit. Of these, sinus rhythm at 12 months explained 81% of the treatment effect of ERC compared with usual care during the remainder of follow-up (4.1 years). In patients not in sinus rhythm at 12 months, ERC did not reduce future cardiovascular outcomes. Inclusion of AF recurrence in the model only explained 31% of the treatment effect, and inclusion of systolic blood pressure at 12 months only 10%. There was no difference in outcomes in patients who underwent AF ablation compared with those who did not undergo AF ablation (Figure 1). The authors conclude that in the EAST-AFNET 4 trial, the effectiveness of early rhythm control is mediated by the presence of sinus rhythm at 12 months. Clinicians implementing ERC should aim for rapid and sustained restoration of sinus rhythm in patients with recently diagnosed AF and cardiovascular comorbidities. The contribution is accompanied by an Editorial by Dominik Linz, from the Maastricht University Medical Centre and Cardiovascular Research Institute Maastricht in The Netherlands, and William McIntyre from McMaster University in Hamilton, Canada.6 The authors point out that in general, the implementation of ERC will require a multidisciplinary approach with a shared decision-making process to discuss the